Brief: ImmunoGen Says Elahere Shows Overall And Progression-Free Survival Benefit In FRα-Positive Platinum-Resistant Ovarian Cancer
28/09/2023 12:30
Sept 28 (Reuters) - ImmunoGen Inc IMGN.O :
* ELAHERE® SHOWS OVERALL AND PROGRESSION-FREE SURVIVAL
BENEFIT
REGARDLESS OF PRIOR PARPI EXPOSURE OR PRIOR LINES OF THERAPY IN
FRΑ-POSITIVE PLATINUM-RESISTANT OVARIAN CANCER
Source text for Eikon: ID:nBw1qSxkxa
Further company coverage: IMGN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on ImmunoGen
See all newsBrief: Abbvie Completes Acquisition Of Immunogen
Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77
Brief: Immunogen Says German Federal Cartel Office Approved Merger With Abbvie Unconditionally
Ambrx Biopharma surges on J&J's buyout announcement
Street View: BioMarin-Elliott settlement likely eases investor frustration